ARTICLE | Emerging Company Profile
San Diego-based company’s antibody-lectin chimeras act as molecular decoys to disrupt cellular interactions
By Richard Guy, Biopharma Analyst
November 27, 2024 9:52 PM UTC
Launched this month with a $30 million seed round co-led Avalon, Bregua and TigerGene, Valora has a new take on blocking immune evasion by cancer cells. The start-up views the pattern of sugar molecules on the surfaces of tumor cells as a code used to fool the immune system and is developing chimeric antibodies capable of disrupting the evasion signal.
Tumors remodel their cell surface glycosylation patterns for a variety of reasons, one of which is to facilitate engagement with sugar-binding immune checkpoints, enabling the cancer to avoid an immune attack as it continues to grow. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654189/valora-blocking-cancer-s-immune-evasion-via-glycan-targeting